Jung Choi
Entrepreneur-In-Residence, Third Rock Ventures
Ms. Choi serves as an Entrepreneur-In-Residence at Third Rock Ventures. She is passionate about transforming people’s lives by delivering the best medicines science can create. Jung has led at the intersection of science and business. Prior to TRV, she was Chief Business & Strategy Officer at Global Blood Therapeutics (acquired by Pfizer), where she led Corporate Development, R&D Program Management & Portfolio Strategy, Patient Advocacy and Government Affairs/Policy, and was instrumental in building a pipeline of novel therapies for sickle cell disease.
Prior to GBT, she served as SVP Corporate Development at InterMune, Inc. (acquired by Roche) and SVP Corporate Development at Chimerix, Inc. She has held various management positions of increasing responsibility at Gilead Sciences, Inc., including leadership of worldwide business development, licensing and mergers and acquisition. During her tenure, she built and oversaw the corporate development group and led the U.S. commercial launch of Hepsera® for the treatment of chronic hepatitis B. She also has venture capital and strategy experience, having served as a vice president at Bay City Capital and an engagement manager at McKinsey & Company. She has led or managed >50 transactions exceeding $17 billion in value.
She currently serves on the Board of Annexon (NASDAQ: ANNX), Marea, New York Blood Center, and California Life Sciences. She is an Aspen Institute Health Innovator Fellow, and received a B.A. in human biology and an M.B.A. from Stanford University.